Alternative splicing changes the Ca V 1.2 calcium channel electrophysiological property, but the in vivo significance of such altered channel function is lacking. Structure-function studies of heterologously expressed Ca V 1.2 channels could not recapitulate channel function in the native milieu of the cardiomyocyte. To address this gap in knowledge, we investigated the role of alternative exon 33 of the Ca V 1.2 calcium channel in heart function. Exclusion of exon 33 in Ca V 1.2 channels has been reported to shift the activation potential −10.4 mV to the hyperpolarized direction, and increased expression of Ca V 1.2 Δ33 channels was observed in rat myocardial infarcted hearts. However, how a change in Ca V 1.2 channel electrophysiological property, due to alternative splicing, might affect cardiac function in vivo is unknown. To address these questions, we generated mCacna1c exon 33 −/− -null mice. These mice contained Ca V 1.2 Δ33 channels with a gain-of-function that included conduction of larger currents that reflects a shift in voltage dependence and a modest increase in single-channel open probability. This altered channel property underscored the development of ventricular arrhythmia, which is reflected in significantly more deaths of exon 33 −/− mice from β-adrenergic stimulation. In vivo telemetric recordings also confirmed increased frequencies in premature ventricular contractions, tachycardia, and lengthened QT interval. Taken together, the significant decrease or absence of exon 33-containing Ca V 1.2 channels is potentially proarrhythmic in the heart. Of clinical relevance, human ischemic and dilated cardiomyopathy hearts showed increased inclusion of exon 33. However, the possible role that inclusion of exon 33 in Ca V 1.2 channels may play in the pathogenesis of human heart failure remains unclear.
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CaV1.2 channel | alternative splicing | cardiac function | cardiac arrhythmia | heart failure T he L-type Ca V 1.2 calcium channels are critically important for the initiation of muscle contraction. Structural variations of Ca V 1.2 channels generated via alternative splicing diversify channel electrophysiological properties to optimize their function (1, 2) . Inclusion of cassette exon 33 shifts the activation potential of the Ca V 1.2 channel, and this variant will require larger depolarization of membrane potential to open. Notably, exon 33 is regulated developmentally, and its expression is altered by pathology such as myocardial infarction (2) (3) (4) .
Structure-function studies have been performed of Ca V 1.2 channels heterologously expressed in cell lines or in isolated cardiomyocytes, but results from these in vitro experiments may not inform in vivo relevance (5, 6) . The major reason is because it is almost impossible to reconstitute a native in vivo milieu in cell lines that have heterologously expressed a defined combination of the subunits that compose the Ca V 1.2 channel complex.
The electrophysiological properties of the Ca V 1.2 channels can be diversified by the association with one of four β-subunits or one of four α2δ-subunits. To further expand the range of diversification, each of the subunits could be alternatively spliced and posttranslationally modified. As such, at best, one could make predictions from in vitro results of in vivo significance; however, work done on the Ca V 1.2 channels has not produced such results, and there are still many controversies and contradicting published data (5, 6) .
To directly address in vivo significance of altered Ca V 1.2 channel property arising from alternative splicing, we have generated exon-specific knockout mice deleting alternative exon 33 of the L-type Ca V 1.2 channel. Questions have been asked about the importance that a modest voltage-dependent change in electrophysiological properties of ion channels has on physiology. In this study, we show dramatic effects on cardiac function arising from a voltage shift in activation potential of the Ca V 1.2 Δ33 channels. The hearts of the exon 33-null (exon 33 −/− )
Significance
To directly address in vivo significance of the altered Ca V 1.2 channel property arising from alternative splicing, we generated Ca V 1.2 exon 33-specific knockout (exon 33 −/− ) mice. Here, we showed that the exclusion of alternative exon 33 altered Ca V 1.2 biophysical property, leading to greater I Ca density. This increase in current density induced prolongation of ventricular cardiomyocyte action potential duration, and the cardiomyocytes exhibited increased early afterdepolarizations and autonomous action potentials-hallmarks of arrhythmias. In vivo, exon 33 −/− mice had increased occurrences of premature ventricular contractions, tachycardia, and lengthened QT interval. As such, exclusion of exon 33 of the Ca V 1.2 channel is proarrhythmogenic. Although failing human hearts had greater inclusion of exon 33, it is unclear whether the inclusion is compensatory, neutral, or damaging.
mice were found to develop ventricular arrhythmias. Whereas echocardiographic and pressure-volume measurements showed increased contractility, in vivo telemetric recordings showed increased frequency in premature ventricular contractions and spontaneous ventricular tachycardia. The underpinning mechanisms for these cardiac defects are larger current densities of the Ca V 1.2 Δ33 channels due to a left-shift of activation potential, a modest increase in single-channel open probability (Po), and a shorter closed time.
Results

Exon 33
−/− Cardiomyocytes Have a Similar Surface Expression of Ca V 1.2 Channels. Exon 33 −/− mice were generated by cremediated genetic targeting (7) to remove exon 33 from the mCacna1c gene ( Fig. 1A and SI Appendix, Fig. S1A ). The mice were genotyped as WT ( +/+ ), heterozygous (
), and homozygous (
−/−
) by the predicted restriction-enzyme fragments of 10.0 kb for WT (+) and 8.0 kb for null (−) alleles (Fig. 1B) . To examine the exon 33 deletion in the mCacna1c transcripts, we used RT-PCR to detect a 351-bp PCR product for WT, a 318-bp PCR product for null, and 351-and 318-bp products for heterozygotes (Fig. 1C) , and these results were confirmed by DNA sequencing (SI Appendix, Fig. S1B ).
Genetic deletion of exon 33 also did not alter the Ca V 1.2 transcript levels as examined by real-time PCR of mRNAs isolated from the left ventricles (SI Appendix, Fig. S1C ). Of note, immunolabeling with pan-Ca V 1.2 antibody revealed typical striation patterns in isolated cardiomyocytes (SI Appendix, Fig. S1D ) without obvious signs of hypertrophy at 6 mo. Importantly, the total protein of Ca V 1.2 in whole heart (SI Appendix, Fig. S1E) and the surface expression level of Ca V 1.2 in isolated cardiomyocytes ( Fig. 1 D and  E) was unaltered, providing assurance that deletion of exon 33 did not alter surface expression of the Ca V 1.2 channels.
To ascertain that genetic targeting of exon 33 did not affect other alternative splicing events, we used restriction enzyme digestions and/or amplicon sizes of RT-PCR products to determine levels of expression of alternative exons. The major alternative exons of transcript-scanned mCacna1c were found to be unchanged in expressions except that mutually exclusive exon 32 was expressed at a higher level in exon 33 −/− hearts (SI Appendix, Fig. S2 ). However, we have shown previously that the inclusion of mutually exclusive exon 31 or 32 did not change the electrophysiological properties of the Ca V 1.2 channels (2, 8) . To further analyze the combinatorial splicing patterns in the exon 33 −/− mice, we generated a pool of full-length Ca V 1.2 cDNAs (9), and, using appropriate pairs of primers, we colony-screened to detect the inclusion and exclusion of nine alternative exons of each cDNA clone expressed in Escherichia coli. Our results showed that the splicing combinations of the cardiac Ca V 1.2 channels remained similar, except for the loss of exon 33 and the higher expression of exon 32 over exon 31 (SI Appendix, Table S1 ).
As our objective was to assess cardiac function, we measured the protein levels of known ion channels required for the generation of the ventricular action potentials (APs) and found that their expression levels were similar (SI Appendix, Fig. S3A ). Moreover, the hearts of WT and exon 33 −/− mice were morphologically similar with no obvious signs of hypertrophy at 6 mo of age (SI Appendix, Fig. S3 B-E). To evaluate global transcript expressions between WT and exon 33 −/− hearts, our microarray experiments did not show any significant changes in transcripts that are important in Ca 2+ homeostasis (SI Appendix, Tables S6-S8) . No significant differences were detected for calcium channel α 2 δ-or β-subunits or for protein phosphatases (SI Appendix, Tables S9-S11). These combined data suggest that any changes in cardiac AP property would be due largely to the altered characteristics of Ca 2+ current (I Ca ) fluxing through the Ca V 1.2 Δ33 channels (10).
Exon 33
−/− Ca V 1.2 Currents in Cardiomyocytes Are Larger. To determine the underlying mechanism for the phenotypes in the exon 33 −/− hearts, we performed electrophysiological recordings in isolated cardiomyocytes and found that the current density was increased by 33% ( Fig. 2 A and B) and that the steady-state activation and inactivation potentials of I Ca were left-shifted ( Fig. 2 C and D) . This gave rise to a calcium window-current that peaks at −24 mV for exon 33 −/− mice, which is 12 mV more hyperpolarized than WT (Fig. 2D) . The larger electrochemical force for the Ca V 1.2 Δ33 channels accounted for the larger current density recorded in exon 33 −/− cardiomyocytes (1.99 pA/pF). The half-activation potential (V 0.5 ) was also left-shifted by 10.1 mV, suggesting that the Ca V 1.2 Δ33 channels were more easily opened upon depolarization from rest (Fig. 2B) ; however, the rate of recovery from inactivation was similar (SI Appendix, Fig. S4 A  and B) . However, the ventricular AP-triggered calcium currents, as recorded in whole-cell voltage-clamp mode, were nonetheless 60% larger in the exon 33 −/− cardiomyocytes ( Fig. 2 E and F) . cardiomyocytes could be explained by an increase in surface expression, which we had earlier excluded; a shift in voltage dependence, which we have shown in Fig. 2 and previously reported for Ca V 1.1 channels (11); or a modest increase in maximum Po of the Ca V 1.2 Δ33 channels (12, 13). Single-channel recordings showed increased channel activity in the exon 33
cardiomyocytes at +10 mV ( Fig. 2G ) and over several test potentials (SI Appendix, Fig. S4C ), which also indicated a modest (Fig. 3A) , and application of 10 nM nifedipine blocked exon 33 −/− I Ca by ∼15% more than WT (Fig. 3B) . These results substantiated the third mechanism that we proposed for nifedipine blockade in which an altered biophysical property of the Ca V 1.2 channels due to alternative splicing is associated with sensitivity to blockade by nifedipine (4) . The other two mechanisms are due to inclusion of mutually exclusive exon 8 or 8a that encodes the DIS6 segment and the more depolarized resting potential of smooth muscle compared with cardiac muscle. However, the responses to β-adrenergic stimulation were similar between WT and exon 33 −/− cardiomyocytes, unlike in human heart failure (13) (Fig. 3 C and D) . Application of isoproterenol (ISO) slightly left-shifted I-V curves of both WT and exon 33 −/− Ca V 1.2 channels (Fig. 3E ), but an increase in I Ca was not different for various concentrations of ISO used (Fig. 3F) . Similarly, use of a range of concentrations of foskolin also resulted in comparable increases of I Ca in WT and exon 33 −/− cardiomyocytes (Fig. 3G ). 4 A and D) . Application of 100 nM nifedipine reduced the APD 90% in exon 33 −/− cardiomyocytes significantly but not in WT (Fig. 4 A and E), suggesting that the repolarizing potassium currents were not affected (17). The resting membrane potential was similar in WT and exon 33 −/− cardiomyocytes (Fig. 4B) , although the refractory period in exon 33 −/− was longer by ∼40% (Fig. 4C ), which could be attributed to the slower repolarization of the AP.
The occurrence of early after-depolarization (EAD), an indicator of cardiac arrhythmia, which could be mediated by prolonged APD and reactivated Ca 2+ influx through Ca V 1.2 channels (18, 19), was increased by 2.7 times in exon 33 −/− over WT cardiomyocytes (Fig. 4  F and G) . This result is in agreement with a previous report that showed that generation of EAD was highly sensitive to shifts in activation potential of L-type calcium channels (20). Another indicator of cardiac dysfunction is the generation of autonomous APs after the cessation of electrical stimulation, and again the exon 33 −/− cardiomyocytes showed increased frequency of 3.4 times over WT (Fig. 4 H and I Contractility. To examine in vivo significance, we paced the intact heart electrically with the application of ISO (1 mg/kg, i.p. injection) (23) and detected that exon 33 −/− hearts were more susceptible to the generation of ventricular tachyarrhythmia (Fig.  5A ) (24). Half of the exon 33 −/− mice developed ventricular tachyarrhythmia, whereas none of the WT did (Fig. 5B) , for a duration of ∼1 s (Fig. 5C) . Examination of heart function by echocardiography showed no differences in left-ventricular-wall thickness, chamber dimensions, and mass, but there was significantly higher left ventricular ejection fraction (LVEF: 77 ± 6% vs. 73 ± 7%), greater fractional shortening (40 ± 5% vs. 36 ± 6%), and higher cardiac output (CO: 16 ± 4 vs. 13 ± 3 mL/min) in the exon 33 −/− mice (SI Appendix, Fig. S5 and Table S3 ). Furthermore, we analyzed the pressure-volume (P-V) conductance by Millar catheter, and consistent with echocardiographic measurements, P-V loop data indicated that exclusion of exon 33 in Ca V 1.2 channels significantly increased cardiac contractility (LVEF: 49 ± 8% vs. 40 ± 7%) and output (CO: 13.8 ± 4.2 vs. 9.1 ± 3.5 mL/min) in the exon 33 −/− mice compared with WT mice (SI Appendix, Table S4 ).
The enhanced cardiac contractility is correlated with increased electrically induced Ca 2+ transients (SI Appendix, Fig. S6 A and B Fig. S6C ). Although the spark amplitude and frequency were similar, there were significant augmentations in spark spatial width (full width at half maximum) and temporal duration (full duration at half maximum), indicating increased elemental Ca −/− mice was ∼73% longer than for the WT mice ( Fig. 5 G and H), whereas the heart rate was slightly higher (Fig. 5I) . Overall, the in vivo consequence of the altered Ca V 1.2 channel property owing to the absence of alternative exon 33 was proarrhythmogenic. The QA interval, which is an indicator of contractility, was lower in exon 33 −/− mice ( mice died at a threefold higher frequency than WT littermates (Fig. 6A ). The gross morphology of the exon 33 −/− ISO-treated hearts was much larger and the weight was heavier, but not the heart:body mass ratio ( Fig. 6 B and C). These data clearly demonstrated that the β-adrenergic effect was still intact in the exon 33 −/− hearts and that activation of the β-adrenergic receptor exacerbated the cardiac electrical phenotype of the exon 33 −/− mice.
Human Heart Failure Has Significantly Higher Expression of Exon 33. To relate the mouse data with potential clinical relevance, we characterized exon 33 expressions in human nonfailing and failing hearts (SI Appendix, Table S5 ). Single-channel recordings of human nonfailing and failing hearts have been reported (13), and failing cardiomyocytes displayed little change in expression of the Ca V 1.2 α 1 -or β-subunits but a defect in dephosphorylation. We extracted mRNAs from human hearts, including those previously reported (13), to determine the expression level of Ca V 1.2 exon 33 ( Fig. 6D ) and found that in nonfailing heart (Fig. 6 D and E) the expression level was ∼60%, which is similar to normal adult human heart (2, 4, 9). In contrast, the inclusion of exon 33 increased significantly by ∼20% in human ischemic and dilated cardiomyopathy failing hearts (Fig. 6D , Middle and Lower, and E).
Discussion
The difficulty of interpreting in vitro results for in vivo significance is strikingly reflected in the controversies and uncertainties that still exist after 20 y of research on β-adrenergic regulation of the Ca V 1.2 channels (5, 6). Clearly, in vitro conditions cannot recapitulate the cellular milieu or physiological context by which Ca V 1.2 channels function properly in native cardiomyocytes. To complicate matters, native channel properties could be diversified by posttranscriptional or posttranslational modifications, which again cannot be fully mimicked in in vitro experiments where cloned Ca V 1.2 channel subunits are heterologously expressed in cell lines that are of noncardiac origin. -null mice has provided direct evidence that a shift in cardiac Ca V 1.2 channel activation in the hyperpolarized direction has profound effects on native cardiac membrane excitability leading to adverse heart rhythmicity and enhanced muscle contractility. Curiously, the expression of exon 33 of the Ca V 1.2 channel is ∼60% in human heart in contrast to ∼90% expression in rodents (2) . As such, in humans there is a wider dynamic range for variation in exon 33 expression levels to produce an adaptive, deleterious, or protective effect (inclusion of exon 33), as exon 33-containing Ca V 1.2 channels allow reduced Ca 2+ influx. This notion is supported by the increased inclusion of exon 33 in Ca V 1.2 channels found in human failing hearts. The proportion of Ca V 1.2 transcripts with exon 33 was increased from ∼60% in nonfailing hearts to ∼80% in failing hearts. A possible interpretation is that increased expression of Ca V 1.2 33 channels could be a compensatory response to heart failure in humans. In human heart failure, the loss of T-tubules could lead to a remodeling and redistribution of Ca V 1.2 channels from the dyadic junctions to the caveolae membrane (25-27) and might contribute to arrhythmogenesis. The inclusion of exon 33 in Ca V 1.2 channels as shown by our data is antiarrhythmogenic and would therefore suggest a compensatory effect.
In this report, there are a few unexpected observations that are also of clinical relevance. First, unlike overexpressed Ca V 1.2 transgenic murine models where the Po of the channels was either smaller (28) or remained the same (29), our data showed a modest increase in Po, supporting the evidence that increased Po of cardiac Ca V 1.2 channels could contribute to failing human hearts, although the previously reported results were due mainly to hyperphosphorylation of the channels (13). Second, a totally unexpected result was the lack of hypertrophy in the 6-mo-old exon 33 −/− mice. This is in sharp contrast to the Ca V 1.2 α 1 -or β 2 -overexpressed transgenic mice where hypertrophy was observed at 6 mo and the mice died before 12 mo of age from heart failure (30-33). Similar modest Ca 2+ influx was reported by us and Muth et al. (30) , and yet there was a drastic difference in pathology. One explanation could be that nonconducting effects of Ca V 1.2 channels may signal to trigger expression of hypertrophy genes (34, 35), or the distribution of Cav1.2 channels to specific domains within the cardiomyocytes may play a role (25, 26). Third, the β-adrenergic effect was not blunted over the range of concentrations of ISO used in our exon 33 −/− myocytes, unlike what was reported in Ca V 1.2 overexpression transgenic mice or in human heart failure. Our microarray results showed that the Ca V β 2 subunit or calcineurin (PP2A) transcript levels did not decrease, which may explain the preservation of the β-adrenergic stimulation of Ca V 1.2 activity. Interestingly, the coupling efficiency between Ca V 1.2 channels and ryanodine receptors (RyRs) may be increased as Ca 2+ transients and the duration of the Ca 2+ sparks were larger in exon 33 −/− cardiomyocytes (29). The exon 33 −/− mice did not exhibit any of the characteristics of human heart failure such as severe hypertrophy or attenuation of β-adrenergic signaling. Instead, the electrical remodeling of the Ca V 1.2 channels contributed more toward cardiac arrhythmia.
In mouse cortical neurons, increased Rbfox1/2 proteins have been shown to developmentally enhance the inclusion of exon 33 in Ca V 1.2 channels (36). Therefore, of general interest is the decrease in Rbfox1 expression in human and mouse failing hearts (37), but in our human data, the exon 33 level was increased, and it is possible that Rbfox1 regulation of human exon 33 inclusion is different from mice. However, of specific interest is the possibility of variations or mutations within the Rbfox1 binding site (UGCAUG) (38) that might produce moderate effects on cardiac function under normal conditions through the modulation of exon 33 inclusion or skipping, but might trigger arrhythmia when stressed. Ca 2+ homeostasis in heart failure has been reported to be maintained by a few possible mechanisms, namely a decrease in expression of Ca V 1.2 (12), an increase in expression of Na + /Ca 2+ exchanger (NCX) (29), or a decrease in expression of the β 2 subunit (28). Here, we show a mechanism where Ca 2+ homeostasis is influenced by the altered utilization of alternative exon 33 to decrease Ca 2+ influx and may produce an antiarrhythmogenic effect in human heart failure (13).
The exon 33
-null mice are highly unique as the electrical property of the ventricular AP has been altered with dire consequences. In contrast, cardiac-specific overexpression of Ca V 1.2 α 1 -or β-subunits by different groups did not yield consistent results in the phenotype characterization of heart failure (28, 30, 33, 39). Although these transgenic mice died from heart failure within 12 mo as a result of hypertrophy, our exon 33 −/− mice have been maintained and lived past 2 y of age. Our microarray results also showed that the expression levels of the Ca V β-subunits, Ca V α 2 δ-subunits, NCX, sarco/endoplasmic reticulum CaATPase, phospholamban, and RyR transcripts remained relatively unchanged, providing strong suggestion that Ca 2+ handling within the cardiomyocytes was not adversely affected. In summary, it is possible that the gain-of-function of Ca V 1.2 Δ33 channels, when expressed at the crest of ventricular myocytes, contributed to the proarrhythmic triggers, but expression at the T-tubules did not significantly affect coupling to the RyRs to produce hypertrophy (26).
In conclusion, we have provided direct evidence for the in vivo significance of the altered Ca V 1.2 channel property due to alternative splicing.
Materials and Methods
Construction of Targeting microinjection into C57BL/6J mice blastocysts. The germline chimeras with agouti color were crossed with C57BL/6J mice into the fourth to fifth generations. Male littermates with the same genetic background were used for experiments. All animals were treated ethically in accordance with the approved institutional animal care and use committee protocol of the National University of Singapore. Isolation of Single Adult Mouse Cardiomyocytes. Single cardiomyocytes were isolated from male adult mouse heart (2-4 mo). The mice were injected intraperitoneally with 1,000 IU heparin and euthanized in a CO 2 chamber. The heart was immediately transferred to precooled Tyrode solution, and the surrounding tissues (including lung) were removed. The aorta was cannulated using 27G blunted needles and tied using 6.0 surgical threads. Then the heart was mounted onto the Langendorff apparatus and it was perfused through the aorta with prewarmed and oxygenated normal Ca 2+ -free Tyrode solution for 5 min. Following this procedure, the heart was perfused with the same solution but containing 0.28 mg/mL Protease Type XIV (P5147, Sigma-Aldrich) and 0.84 mg/mL collagenase type I (C0130, Sigma-Aldrich) for more than 8-10 min. The left ventricle tissue was dissected, diced into small pieces with a pair of small scissors, and gently stirred in a petri dish containing the same normal Tyrode solution without enzyme. The dissociated cells were filtered with a stainless steel cell dissociation sieve (S1145, Sigma-Aldrich) and washed three times by centrifugation. Finally, the Ca 2+ concentration of the Tyrode solution was increased gradually to 1.0 mM in 20 min to maintain the isolated cardiomyocytes in physiological medium (40). Paced Electrocardiography. In vivo cardiac electrophysiology was carried out as described previously (43, 44). Mice were anesthetized by i.p. injection with pentobarbital sodium (45 mg/kg) and immobilized on a heating pad set to 37°C. To maintain physiological breathing and avoid an open-chest operation, a paired unipolar electrode was attached to the ventricle through the diaphragm by an abdominal access. The electrode was connected to a stimulator, and a burst pacing protocol (10 pulses with 40-ms intervals and 1.0-ms pulse width) was applied using twice the amount of voltage of the stimulating threshold. The threshold was determined by pacing the heart with increased voltages at a rate 20% higher than the individual mouse heart rate output. Pacing was started 2 min after i.p. injection of ISO (1 mg/kg). The ECG recording started 2 min before ISO injection and continued for 5 more min after injection. Expression of Exon 33 in Human Ventricular Heart Samples. Five nonfailing (NF) and 10 failing (F) heart samples were obtained from U.C.H. and 2 nonfailing (NF), 16 failing (F) heart samples were obtained by R.F. from the University of Cambridge, Cambridge, UK, and one normal, pooled human heart cDNA purchased from Clontech Laboratories (Takara Bio USA) were used in this study. Institutional IRB approvals for this study were obtained for U. Implications for fibrosis and heart rate in mice. 
Measurements of Local
Supplemental Experimental Procedures
Determination of mouse genotypes and analysis of gene expression Southern blot analysis was used to determine the mouse genotypes. The genomic DNA was extracted from tail clipping and digested using restriction enzyme NsiI. The samples were electrophoresized on a 0.7% agarose gel which was transferred onto a nylon membrane (Hybond-N). The blot was UV crosslinked and hybridized at 42 o C with a DIG (Roche) labeled probe generated via incorporation of a dUTP-DIG label with primers 5'-GCA CTC CAC AGT AGT CAC GTA-3' and 5'-AAG CAA CCC AGA AGT TCT TAT C-3'. Bands were detected using anti-DIG antibodies conjugated to alkaline phosphatase and CDP-star. The skipping of exon 33 in heart tissue at the mRNA level was analyzed by RT-PCR. Total RNA was extracted from heart samples using Trizol reagent (Invitrogen) according to the manufacturer's recommendation. Superscript III (Invitrogen) was used to generate the first strand cDNA from RNA (reverse primer 5'-GGA CTT GAT GAA GGT CCA CAG C-3'). This is followed by amplification by PCR with the same reverse primer and a forward primer 5'-CAC TAT GGC CAG AGC TGC CTC-3'. The samples are resolved in a 4% agarose gel. Real-time PCR was used in quantitative analysis of the Ca v 1.2 channel mRNA expression level between WT and KO mice. FAM labeled mouse Cacna1c probe located at the constitutive exon 4-5 (Assay ID Mm00437913_m1, Applied Biosystems). Mouse ACTB (actin, beta) was used as endogenous control (FAM™ Dye/MGB Probe, Applied Biosystems).
Cell surface biotinylation and western blotting
Cell surface proteins from mouse cardiomyocytes were isolated using the Cell Surface Protein Isolation kit (Pierce) following the manufacturer's protocol with minor modification for suspension cells. The biotinylated cardiomyocyte pellets were fully lysed and equal amounts of lysates from WT and KO mouse hearts were incubated separately with immobilized NeutrAvidin Gel to purify biotinylated membrane proteins, which were then separated in 6% SDS PAGE gel and transferred overnight. The PVDF membrane was blocked with 5% skim milk and further incubated with primary antibody (AntiCa V 1.2, Alomone Labs) at 1:1000 dilutions, followed by HRP-conjugated secondary antibody (Sigma) at 1:6000 dilutions. The membrane was incubated with ECL before exposure on an X-ray film. The total protein of left ventricles of the hearts from wild type and exon 33 -/-mice were homogenized in lysis buffer containing 150 mM Tris pH 7.5, 3 mM MgCl 2 , 10% Glycerol, 1% Triton X-100, 1 mM EGTA, 1 mM EDTA, 0.5 M NaCl and the complete protease inhibitor cocktail (Roche). The lysate was further sonicated for 5 sec at 40% amplitude. The samples were then centrifuged at 13,000 rpm for 15 min and the supernatant was collected, followed by determination of the protein concentration. All procedures were carried out at 4 o C.
Restriction Profile of splice variants of WT and exon 33 -/-KO mice Total RNA was isolated from heart tissues of WT and exon 33 -/-mice using Trizol reagent (Invitrogen). Reverse transcription was performed using Superscript III (Invitrogen). A touchdown PCR, using GoTaq o C for 10 min. Gel electrophoresis was performed on exon 9-12 PCR product and inclusion/exclusion of exon 9* can be identified via size difference. Mutually exclusive exon 8/8a was identified by digesting exon 7-9 PCR product with restriction enzyme BamHI while exon 21/22 was identified by digesting exon 19-26 PCR product with AvrII. Lastly, exon 31/32 was identified by digesting exon 29-36 PCR products with NsiI.
Inclusion of exon 33 could also be detected by an increase in band size and confirmed by automated DNA sequencing.
Histological analysis and immunohistochemistry
The heart of mice were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). For immunofluorescent staining, acutely isolated cardiomyocytes, seeded on cover-slips, were washed with phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde in PBS for 15 min at room temperature, washed in PBS once, washed with 100 mM NH 4 Cl in PBS twice and washed again with PBS (X2). They are then permeabilized (0.2% trition X-100 in 1× PBS) for 15 min and blocked for 1 hour (1× PBS, 2% BSA, 5% FBS). The fixed cells were then incubated at 4 o C overnight with primary Ab (Ca V 1.2 rabbit polyclonal, 1:200 dilutions, ACC-003, Alomone Labs). After washing with 1× PBS thrice, goat anti-rabbit Alexa Fluor 488 (1:200 dilutions, Invitrogen) conjugated secondary antibody was added to the samples and incubated for 1 h at 25°C. The slides were visualized using a laser scanning confocal microscope system at 25°C.
Generation and analysis of full-length cardiac Ca V 1.2 cDNA clones by PCR. Total RNA was isolated from left ventricles of one WT and two exon 33 -/-mice using RNeasy Kit (QIAGEN). Reverse transcription was performed using Superscript III (Invitrogen). EXL polymerase (Agilent Technologies) was used to amplify regions between exon 1a and exon 50 of the Ca V 1.2 gene using primers (1) Transcript scanning were performed to identify the splicing profile at 8 alternatively spliced loci, namely exon 8/8a, exon 9*, exon 21/22. Exon 31/32 and exon 33. Inclusion/exclusion of exon 9* were detected using exon 7 ('5-GTG TAT CAC CAT GGA GGG CTG G-3') primer and exon 11 ('5-CTG AAT TTG GAT TTG GAG ATC CGA TGG-3'). A 393 bp amplicon indicated the presence of exon 9* while a 318 bp amplicon indicated the absence of exon 9*. A similar approach was used for exon 33 using exon 30 primer ('5-CAC TAT GGC CAG AGC TGC CTC-3') and exon 34 primer ('5-GGA CTT GAT GAA GGT CCA CAG C-3'). An increase of 33 bp in band size will indicated the presence of exon 33. As mutually exclusive exons have identical size, sequence-specific primers were employed to identify them. PCR was performed using exon 11 primer and exon 8-specific primer (5'-GTC AAT GAT GCC GTA GGA AGG-3') or 8a -specific primer (5'-ATG CAA GAC GCT ATG GGC TAT-3'), generating a 394 bp amplicon. Likewise, a 173 bp fragment generated by exon 23 primer (5'-GGA TGC CAA AGG AGA TGA GG-3') and exon 21 specific primer (5'-TAC CAC CAT TTT CAC CAT TGA AAT TGC-3') or 22 specific primer (5'-AGG CAA TGC AGA CTA TGT CTT CAC TAG TAT C-3') is used in the exon 21/22 loci. Lastly, exon 34 primer and exon 31 (5'-AAT TGA TGT CAT TCT CAG TGA GAC TA-3') or exon 32 (5'-TGT TGA TAT AGC AAT CAC CGA GGT AC-3' is used in the 31/32 loci.
Whole-cell electrophysiological recording
Whole-cell L-type calcium current (I Ca ) of exon 33 -/-and wild type cardiomyocytes were recorded using the patch clamp technique (2) . The external solution for I Ca recording contained (in mM): tetraethylammonium (TEA) 120, HEPES10, MgCl 2 1.0, CsCl 10, glucose 10, CaCl 2 1.8, pH adjusted to 7.4 with CsOH. The internal solution contained (in mM): Cs-MeSO 3 138, CsCl 5, EGTA 0.5, MgCl 2 1, MgATP 4 and HEPES 10, pH adjusted to 7.3 with CsOH. Whole-cell currents were sampled at 10 kHz and filtered at 2 kHz. Data analysis and curve fitting were performed with GraphPad Prism IV software (San Diego). The current-voltage (I-V) relationship was obtained from a holding potential of -55 mV, starting with 0.5 s depolarizing pulses to different membrane potential (10 mV increments from -50 mV to +60 mV), followed by a second 10 mV and 0.2 s depolarizing test pulse for inactivation studies. The I-V curves were generated from the first pulse currents and fitted by I/I max =G max (V-E rev )/{1+exp[(V-V 1/2 )/K I-V ]}, where I is the first pulse current, I max is the normalized peak current, G max is maximum conductance, E rev = reversal potential, V 1/2 is the voltage at 50 % of Ca 2+ current activation, and K I-V is slope factor. The voltage-dependent activation curve was also generated from the current of first pulse by fitting the equation G/G max =I/ {I+exp[(V h -V)/K]} whereas the voltage-dependent inactivation curves were generated from the ratio of the second test pulse current to the first test pulse current and fitted by I/Imax= I/{I+exp[(V-V h )/K]}. The junction potential was measured as -14.4 mV, which was not corrected in our presented data. Whole-cell recording of action potentials was carried out in the current-clamp mode. The extracellular bath contained (in mM): NaCl 137, KCl 5.4, MgCl 2 1, NaH 2 PO 4 0.33, HEPES 10, glucose 10, CaCl 2 1.8, pH adjusted to 7.4 with NaOH. The pipette (3-5 MΩ) solution contained (in mM): potassium gluconate 123, NaCl 9, MgCl 2 1.8, EGTA 0.9, HEPES 9, phosphocreatine 14, MgATP 4, pH adjusted to 7.2 with KOH. To trigger action potentials, currents were injected and increased gradually from 0.5 nA to test threshold. A 1.3 time threshold current was used to trigger single or a train of action potential at 0.5 Hz to 10 Hz rate (3).
Cell-attached single-channel recording
Single-channel recordings were carried out in the cell-attached configuration using an Axopatch 200B amplifier (Molecular Devices) as reported previously (4) . Data were filtered at 2 kHz (-3 dB, 4-pole Bessel) and sampled at 10 kHz. Cells were depolarized with (in mM): BaCl 2 70, sucrose 110 and HEPES 10, pH 7.4 (TEA-OH) for 150 ms from a holding potential of -100 mV to various test potentials (-10 mV -+20 mV). Pulse frequency was 1 kHz to fully allow for recovery of the channels in the patch. To collapse the membrane potential a high-potassium-rich bath solution was used containing (in mM): Kglutamate 120, KCl 25, MgCl 2 2, HEPES 10, EGTA 2, CaCl 2 1, Na 2 -ATP 1, glucose 10, pH 7.4 (KOH). Thermal noise was reduced by heavy elastomeric coated pipettes (borosilicate glass, 6-7 MΩ) using Sylgard 184 ® (Dow Corning). The pClamp10 software package was used for the data acquisition and analysis. All experiments were carried out at ambient temperature (23-25 o C). Single-channel events were detected using the half-height criterion (5, 6) and raw data were digitally leak and capacity-corrected. The number of channels in the patch was estimated by the occurring number of staged openings recorded over several minutes at different test potentials (-20 mV, -10 mV, 0 mV, 10 mV, 20 mV). For statistical analysis a minimum of 180 traces was recorded for each experiment at different test potentials when possible. NP open (k<2) was plotted from five continuous experiments over a serious of test potentials (see supplementary data) and fitted with a single Boltzmann function as reported previously (7) . Mean ensemble average current was derived from 180 traces (n=1 cell) whereas the local maximum (I peak ) was estimated by using a simple smoothening algorithm (Fast Fourier transformation) to abolish high frequency noise. Fraction of active sweeps (availability) was calculated by the number of active traces (Mactive) divided by the total number of sweeps (M0). Dwell-time histogram binning was performed according to Sigworth and Sine (6) and fitted with a mean simplex method. Statistics is based on four animals (6-8 months) of each phenotypic group with real single-channel experiments (k=1 channel) only. Pooled data are shown as mean values with standard error. Data were considered as statistical significant at a 95% confidence interval by using Student's t-test.
Measurements of spontaneous Ca
2+ release events and [Ca 2+ ] i transient We used a laser scanning confocal microscope and the fluorescent Ca 2+ indicator Fluo-4 as reported previously (8) to detect Ca 2+ sparks in resting cardiomyocytes bathed in normal Tyrode solution. Briefly, intact cardiomyocytes were loaded with 6 µg/mL Fluo-4 AM (Molecular Probes) for 15 min at room temperature before placement in the experimental chamber (LSM-510, Carl Zeiss). Images were acquired with a 40× oil-immersion objective (numerical aperture, 1.3; excitation at 488 nm; emission > 505 nm). Line-scan (X-T) mode was used with 512 pixels per line at a rate of 3 ms per scan. The scan line was in a line parallel to the longitudinal axis while avoiding nuclei of the cells, and relocated after acquiring six images to reduce damage from laser illumination. Only quiescent myocytes without induced calcium transient during scanning were used. Spontaneous Ca 2+ sparks with bright and crispy appearance were selected for analysis with IDL 5.4 software. Cytosolic Ca 2+ concentration were measured similarly whereas electrical stimulation at 0.2 Hz were used to measure [Ca 2+ ] i changes in the myocytes during cardiac cycle. Both the amplitude of Ca 2+ spark and transient were reported as F/F 0 , where F 0 is the resting or diastolic fluo-4 fluorescence and set by IDL automatically.
Microarray Transcript Profiling
Total RNA were isolated from left ventricle of two WT and two exon 33 -/-mice using the Trizol (Invitrogen) extraction method. The RNA samples were hybridized to a Single-Color Unrestricted Gene Expression Mouse Microarray 4 × 44K (Agilent Technologies, Design ID 14868) chip (service provided by Genomax Technologies Pte Ltd) and detected. The data obtained were analysed by Genespring GX software (Agilent Technologies). Gene expression of calcium channel  2 -, subunits, protein phosphatases and common genes involved in Ca 2+ homeostasis were analyzed. Positive fold changes indicated increase gene expression while negative fold changes indicated a decrease. Data with a fold change of <2 and P-values of >0.02 were considered not significant as indicated by N.S.
Telemetric recordings
Mice were implanted with telemetry devices (HD-X11, Data Sciences International) by a surgery. Briefly, the catheter is placed in the left carotid artery and positioned so that the sensing region of the catheter is in the aortic arch, and two ECG leads are positioned approximately 1 cm to the left of the xyphoid process and the right pectoral muscle subcutaneously to record ECGs. The transmitter portion of the device is positioned along the lateral flank between the forelimb and hind limb of the mouse. After surgery, the mice are allowed to recover for at least 1 week. Then 12 hours nocturnal ECGs from 7 p.m. -7 a.m. were recorded from conscious mice continuously in their native environment and digital data (PhysioTel, Data Sciences International) were stored for future analysis. The QT interval was measured using electronic calipers from five consecutive beats at 12:00 a.m. using the Dataquest analysis software (Data Sciences International), and was corrected for heart rate using a previously validated formula for conscious mice QT/(RR/100) 1/2 (9).
Expression of exon 33 in human ventricular heart samples Total RNA was extracted using Trizol (Invitrogen) as indicated in manufacturer's protocol. Reverse primer 5'-ACA CCT GCA TCC CGA TCA C-3' were used in the synthesis of first strand cDNA with Superscript III (Invitrogen). The first strand cDNA is amplified using Elongase polymerase (Invitrogen) with the same reverse primer and forward primer 5'-GAG CTG CCT GTT CAA AAT CGC-3'. The amplification cycle starts with a denaturation step at 95 o C for 2 min, followed by one cycle of denaturation at 95 o C, 30 sec, annealing at 58 o C, 30 sec and extension at 72 o C, 40 sec. A touchdown PCR protocol was used where the annealing temperature is decreased by 1 o C during each cycle until a final temperature of 53 o C is reached. At the temperature, an additional 35 cycles were maintained and followed by a final extension at 72 o C for 10 min. The amplicons were cloned and colonies screening were performed. To screen for inclusion/exclusion of exon 33, forward primer 5'-CTC TTC ACT GGC CTC TTC ACC-3' and reverse primer 5'-CGG AAG AAG GTG ATG GAG ATG C-3' were used. PCR was carried out using the same amplification protocol as described above using GoTaq ® Flexi DNA Polymerase (Promega). -/-heart while some undigested products remained in wild type heart indicating presence of exon 31. Supplementary Table 1 Splice combination of full-length Ca V 1.2 cDNA library. Full length Ca v 1.2 cDNAs were generated by amplification of mRNA isolated from left ventricle of one WT (+/+) mice and two exon 33 -/-mice. A total of 94 full-length clones were screened from +/+ cDNA while 186 clones were screened from exon 33 -/-. The results showed that the majority of the splice combinations remained unchanged, except for the reduction of exon 31 and absent of exon 33 in exon 33 -/-Ca V 1.2 cDNAs. The proportions of combined splice variants in heart Ca V 1.2 1a-50 cDNA Libraries. "-" indicates the exon is excluded. Table 2 Parameters for single channel recordings at +10 mV. Parameters were based on real single channel events (k=1). Number of experiments (n) was based on 3 (WT) or 6 (exon 33 -/-) mice. Data are presented as mean values and standard error of the mean. The P values were based on an unpaired two-tailed t test (significance level, P<0.05). Table 4 Summary of pressure-volume measurements of WT and exon 33 -/-mice. Abbreviations: HR: heart rate: CO: cardiac output: LVESV: left ventricular end-systolic volume; LVEDV: left ventricular end-diastolic volume; LVESP: left ventricular end-systolic pressure; LVEDP: left ventricular end-diastolic pressure; Tau: relaxation time constant: dP/dtmax: maximum rate of pressure increase; dP/dtmin: maxium rate of pressure decrease; SW: stroke work; LVEF; left ventricular ejection fraction; ESPVR: end-systolic pressure-volume relationship; EDPVR: end-diastolic pressure-volume relationship. *P<0.05 vs WT. Table 5 Patient history of human heart samples from Germany (a) and UK (b). 
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